Skip to main content
. 2011 Jun 15;7(3):282–292. doi: 10.5664/JCSM.1074

Figure 7.

Figure 7

Mean (SD) change from baseline in domains of the MOS Sleep Scalea by visit (mITT Population)

Adjusted mean treatment difference GEn compared with placebo at Week 12 LOCF: GEn 1200 mg: Sleep disturbance, –13.4 (95% CI: –18.5, –8.2; p < 0.0001); Sleep quantity, 0.6 (95% CI: 0.3, 0.9; p = 0.0001); Sleep adequacy, 13.9 (95% CI: 7.0, 20.8; p < 0.0001); Daytime somnolence, –5.4 (95% CI: –10.3, –0.5; p = 0.0309). GEn 600 mg: Sleep disturbance, –11.6 (95% CI: –16.8, –6.4; p < 0.0001); Sleep quantity, 0.3 (95% CI: 0.1, 0.6; p = 0.0209); Sleep adequacy, 13.0 (95% CI: 6.0, 19.9; p = 0.0003); Daytime somnolence, –0.3 (95% CI: –5.2, 4.6; p = 0.8926). ***p ≤ 0.0001; **p ≤ 0.001; *p ≤ 0.01; †p < 0.05. aScale 0–100, except for sleep quantity; decreases in daytime somnolence and sleep disturbance, and increases in sleep adequacy and quantity represent improvements. CI, confidence interval; GEn, gabapentin enacarbil; LOCF, last observation carried forward; mITT, modified intent-to-treat; MOS, Medical Outcomes Study; SD, standard deviation.